Herpes zoster vaccination and vaccine preferences among persons aged 50-64 years in Australia: Findings from a discrete choice experiment.

Vaccine-preventable herpes zoster (HZ) poses substantial burden among Australian adults ≥50 years of age (YOA) despite available vaccination. This study aimed to understand the HZ vaccine-related preferences of adults paying out-of-pocket for HZ vaccination, to facilitate targeted recommendations by physicians and ultimately reduce disease burden. A discrete choice experiment was conducted (March-May 2023) to quantify preferences for HZ vaccine attributes among adults 50-64 YOA: HZ-naïve with selected self-reported comorbidities (n = 525; each comorbidity: n = 75), HZ-naïve without comorbidities (n = 150), and current/former HZ patients (n = 150). Each choice task comprised a "no vaccine" option and three hypothetical HZ vaccine profiles characterized by five attributes with varying levels. Attributes and levels were identified through literature review/concept elicitation/cognitive interviews/expert opinion. The attributes that most influenced HZ vaccine choice (measured by relative importance [RI]) were recommendation by government guidelines/medical societies, then HZ lifetime risk reduction, and protection duration. HZ-naïve adults with comorbidities indicated lower RI of recommendation by government guidelines/medical societies and higher RI of HZ lifetime risk reduction than other respondents. Between HZ-naïve adults without comorbidities and HZ patients, there were no significant differences in RI of each attribute. Respondents with comorbidities, whether overall or grouped by comorbidity, shared identical top three attributes. Between HZ-naïve, HZ-vaccinated adults (n = 146) and those without vaccination (n = 529), each top three attribute (recommendation by government guidelines/medical societies, HZ lifetime risk reduction, and protection duration) showed significantly different RI (p <.001). Findings elucidate the motivations underlying HZ vaccine preferences among Australian adults 50-64 YOA, guiding physician-patient conversations about HZ vaccines.